Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 5.925p 5.85p 6.00p - - - 0 05:30:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 15.5 -1.5 -2.3 - 4.23

Venn Life Share Discussion Threads

Showing 1476 to 1498 of 1500 messages
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
DateSubjectAuthorDiscuss
17/7/2018
13:50
https://uk.advfn.com/cmn/fbb/thread.php3?id=41052994&from=51
elpirata
16/7/2018
15:22
LBO called this and SKIN right SKIN now basically frazzled LBO21 Mar '18 - 08:59 - 45 of 49 0 0 0 What is it they say about the definition of stupidity and repeating the same thing? This is Alltracel all over again and with the same people connected to it so why would we expect a different outcome except more shareholders losing more money.
buywell3
16/7/2018
10:13
Venn, Skin......Mugs. Lets hope the latter have all dried up at least......
cumnor
16/7/2018
07:18
Skin results out today. Within a year the company has basically failed after blowing 2+ million since its IPO. Richardson stepping down & the new CEO & Finance officer are from Cellulac, the company they had just failed to buy. What a murky world AIM has become. Lets see what happens this Friday.
cocker
10/7/2018
14:00
More likely just wants to offload his shares before they go bust
login
10/7/2018
13:44
dont worry the CEO has a plan In the next three years, Richardson wants to see the business exceed €50 million in revenue with full service capability in Europe and a global client base. https://www.irishtimes.com/business/health-pharma/european-expansion-on-the-cards-for-life-sciences-company-1.3556294
elpirata
07/7/2018
11:58
I see SKIN, the VENN spin off has failed with its reverse take over. Having lost some 80% of its value since its IPO, who on earth would participate in another fund raise.
cocker
05/7/2018
10:19
Must say VENN put on a great spread at the Black Rat bar in the City a couple of years ago, Chicken Goujons and a decent claret, went down very well
mr hangman
04/7/2018
12:06
I'm nursing a fourteen grand paper lose in these and I wonder how that's been "invested" for the better to enhance future share holder value by the BOD. No doubt spent on a jolly and liquid lunches!
jpuff
04/7/2018
08:29
More to the point, what can one do about it?!
jpuff
04/7/2018
07:23
Oh What can one possibly say about Venn & the way it has failed to deliver to its shareholders.
cocker
27/6/2018
17:26
Anyone go to the AGM ?
jpuff
25/5/2018
09:20
Just tried some digging on the reverse take over of Cellulac by Skin. Company director has 15 directorships of which 10 have ceased. Cellulac accounts last filed in 2016 & are long overdue. Can not find out without paying, whether Richardson is a shareholder or not. It as if all these guys blatantly pursue acquisitions as a way to hide their failings. What a murky world these men have created.
cocker
17/5/2018
12:58
I suggest everyone looks up the debate about EBITDA and its true or not so true representation of what a business is actually doing. Particularly as I bet that if you look at all the businesses that concentrate on quoting EBITDA and compare them with those that emphasise final profit, you'll get a big difference in performance. It all depends on what you think should or shouldn't be taken off EBITDA. imo EBITDA is a lifeline for businesses struggling to 'escape' exceptionals. "This is what my house would be worth, without the leaking roof and the ongoing legal case about the access road..."
yump
17/5/2018
11:03
Cheers AISHAH. I've also just found this from Davy, who forecast €1.1m EBITDA for this year: Https://www.davy.ie/research/public/article.htm?id=ST2_8081_1.xml.htm "FY results: margin expansion drives EBITDA growth May 17 2018 DAVY VIEW Venn has started to benefit from business integration initiatives and infrastructure investments made in 2017. Greater operational efficiency has driven margin expansion and EBITDA growth. With a full service capability spanning early and late phase clinical projects, we think there is scope to develop new business lines and further increase margins. Additionally, management focus on M&A opportunities has the potential to accelerate growth. We forecast FY 2018 EBITDA of €1.1m and remain ‘Outperform’."
rivaldo
17/5/2018
10:34
.@VennLifeScience (VENN) delivers a solid set of full year numbers. EBITDA more than doubling to €1.0m! In a very strong place to deliver on future growth. @HybridianLLP
aishah
17/5/2018
10:21
The results looked mildly encouraging. Turnover of €17.8m and €1.0m underlying EBITDA is certainly indicative of potential relative to a £4.3m m/cap if VENN's management continue to simplify and transform the company as they have been doing. Especially given they have €1.2m net cash to finance working capital and (from the tone of the narrative) an acquisition. I'd largely written Integumen off almost entirely except as a very long-term possibility, but I do like the look of its potential acquisition/reverse. Let's hope it actually completes (there's a radio silence on this at present, which may be a good or bad thing) - if it does this could just have a material effect on VENN. VENN's outlook is indeed difficult to discern, but perhaps there are clues for those looking for positives in the outlook given the focus on "improved underlying EBITDA", profitability and sunk investment costs which will hopefully pay off this year: "During 2017 our focus has been on the delivered improved underlying EBITDA in the business through improved operational efficiencies. Additional investment in systems means that we now have both the expertise and infrastructure to profitably execute new business in scale and our focus is now on the generation of new business opportunities. We have invested significantly in business development and engaged creatively with clients to develop deeper, longer lasting partnerships and our pipeline of opportunities is healthy. We continue to see an increasing number of opportunities that require the full range of services now on offer in Venn."
rivaldo
17/5/2018
09:24
zzzz just about covers it, a plodder rather than a growth share, they need rns'able material contract announcements to progress
elpirata
17/5/2018
07:51
Yes. 4 months gone and all there is, is the same old mention of 'opportunities'. Positively, it does look like the exceptional for the losses on Integumen covers just about all of it, so the next results should be 'clean'. Quick sanity check: if they ever make about £500,000 profit that would be about 0.8p earnings, which at this current share price would be a p/e of 10 ish.
yump
17/5/2018
07:30
Absolutely nothing on outlook. Very poor.
likitorma
17/5/2018
07:15
Given that the results have taken some 5 months to produce, very surprised no mention of current trading. zzzzzzzzzzzzzzzzzzzz
cocker
16/5/2018
12:08
just took a pop at this for results tomorrow buy showing as sell lol
elpirata
05/5/2018
18:05
I thought the idea was to say: "Don't you mean £18mln yump ? LOL" I didn't except the Spanish Inquisition
yump
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180820 06:49:52